关注并星标CPHI制药在线8月1日,乐普生物宣布与Excalipoin Caymant签订协议,双方就前者两项临床前T细胞衔接器(TCE)资产的知识产权达成合作,Excalipoint将获得这两项产品在全球范围内开发及商业化目标产品的独家权利。乐普生物将收到1000万美元现金首付款;以及获得Excalipoint Cayman扩大后股本的10%普通股,还有总计最高8.475亿美元的开发及商业化...
Source Link关注并星标CPHI制药在线8月1日,乐普生物宣布与Excalipoin Caymant签订协议,双方就前者两项临床前T细胞衔接器(TCE)资产的知识产权达成合作,Excalipoint将获得这两项产品在全球范围内开发及商业化目标产品的独家权利。乐普生物将收到1000万美元现金首付款;以及获得Excalipoint Cayman扩大后股本的10%普通股,还有总计最高8.475亿美元的开发及商业化...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.